Europe's Chemical Legislation Is Delivering—But Do You Know Where You Stand?

For many companies, REACH and CLP are experienced primarily as administrative obligations: deadlines, dossiers, safety data sheets. What these regulations actually achieve—and how far implementation has progressed across Europe—often goes unnoticed. Yet this broader perspective provides valuable orientation, especially for companies looking to align their compliance strategy with long-term regulatory direction.

On 1 June 2026, the European Chemicals Agency (ECHA) published its fourth report on the operation of REACH and CLP in Helsinki. Based on data from 2021 to 2025, the report fulfills a legal requirement under Article 117(2) of the REACH Regulation. The findings are broadly positive—but the report also clearly identifies where the challenges lie.

What the Fourth ECHA Report Shows

REACH and CLP are progressing. The report confirms that implementation continues to move towards its objectives: protecting health and the environment in Europe while supporting innovation and competitiveness. This demonstrates that the regulatory framework is fundamentally working.

A significant shift in focus. While earlier reports centered on REACH registration deadlines, the current reporting period marks a shift towards the systematic examination of substances already in the database. ECHA is now conducting targeted screening and prioritization of substances, generating focused data, and applying structured risk management measures. The result: substances requiring regulatory action are identified and addressed more quickly, contributing to further reductions in emissions and lower exposure for consumers and workers.

CLP is harmonizing safety communication. Uniform classification and labeling of hazardous substances ensures that safety information—from the production floor to the end user—is clear and consistent. Where REACH and CLP processes overlap, the report examines both frameworks together.

But the report also identifies clear weaknesses. Two key challenges are highlighted: first, the availability and quality of data in registration dossiers; and second, a lack of timely updates to registrations—even though these updates are essential for effective evaluation, risk assessment, and chemical management. The increased workload of ECHA's scientific committees is also flagged as a structural limitation of the current framework.

What This Means for Your Business

Progress at the European level does not automatically mean your own compliance management is up to date. The report has concrete implications—particularly for companies that have not reviewed their registrations in years.

1. Dossier quality does not maintain itself
The report explicitly names data availability and quality as a central challenge. ECHA has systematically expanded its evaluation activities in recent years. Incomplete or outdated registration dossiers are increasingly under scrutiny. Gaps here risk not only remediation obligations but also disruptions to market access.

2. Missing updates are a concrete risk
The report explicitly highlights that missing registration updates impede effective REACH implementation. This is a clear signal: companies that have not maintained their dossiers since initial registration—for example, because uses, volumes, or safety information have changed—face growing pressure.

3. Review CLP classifications regularly
Classifications change through new scientific evidence, harmonized classifications (CLH), or amendments to the CLP Regulation itself. A label that was compliant three years ago may no longer be compliant today. Regular reviews are not an optional exercise but a legal necessity.

4. Build supply chain transparency
REACH places obligations not just on registrants but on all actors in the supply chain. Information duties—for example, regarding SVHCs (Substances of Very High Concern)—are being enforced more consistently. Companies that do not communicate effectively within their supply chain risk inadvertently breaching applicable law.

The New Priority: Substances Already Registered

The shift described in the report—from first-time registration to systematic review of registered substances—is a signal that many companies have not yet fully registered. The era of “register and tick the box” is over. ECHA is now practicing active risk management: screening, prioritization, and targeted data requests are standard procedure.

This has implications for business planning. Companies that regard their substances as “registered and done” are underestimating what may still come—and what may already be knocking at the door.

Progress Carries Responsibility

The fourth ECHA report is not an all-clear signal—it is a position statement. Europe has shown that the objectives of REACH and CLP are achievable—and is drawing the appropriate conclusions: scrutiny of registered substances is intensifying, requirements for dossier quality are rising, and enforcement is becoming more consistent.

The encouraging news is that compliance need not be a burden. With the right support, registrations, dossiers, and labeling become a strategic asset rather than a bottleneck.

Want to know where your business stands today? CSB Compliance helps you review and optimize your REACH and CLP compliance—from dossier quality to supply chain analysis. Get in touch now—Rachel Green and Lars Dobbertin are ready to advise you.